|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
TNF inhibitor
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2008
gptkb:FDA
|
|
gptkbp:class
|
gptkb:monoclonal_antibody
|
|
gptkbp:clinical_trial
|
Phase III
chronic inflammatory diseases
|
|
gptkbp:contraindication
|
active infections
hypersensitivity to certolizumab
|
|
gptkbp:developed_by
|
UCBS. A.
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:financial_performance
|
24 months
|
|
gptkbp:formulation
|
lyophilized powder for reconstitution
|
|
gptkbp:frequency
|
every 2 to 4 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
certolizumab
|
|
gptkbp:indication
|
gptkb:psoriatic_arthritis
non-infectious uveitis
|
|
gptkbp:ingredients
|
gptkb:certolizumab_pegol
C742 H1091 N201 O207 S4
|
|
gptkbp:interacts_with
|
gptkb:cyclosporine
gptkb:methotrexate
gptkb:azathioprine
live vaccines
other immunosuppressants
|
|
gptkbp:invention
|
2024
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
tuberculosis screening
|
|
gptkbp:is_used_for
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:marketed_as
|
gptkb:Cimzia
|
|
gptkbp:packaging
|
single-use prefilled syringe
|
|
gptkbp:pharmacokinetics
|
half-life of approximately 14 days
inhibition of TNF-α activity
|
|
gptkbp:population
|
adults
children over 2 years old
|
|
gptkbp:provides_information_on
|
gptkb:ECCO_guidelines
EULAR guidelines
ACR guidelines
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
autoimmune diseases
rheumatology
dermatology
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
liver enzyme elevation
increased risk of infections
injection site reactions
blood disorders
serious infections
malignancies
|
|
gptkbp:storage
|
2 to 8 ° C
|
|
gptkbp:targets
|
tumor necrosis factor alpha (TNF-α)
|
|
gptkbp:traded_on
|
gptkb:Cimzia
|
|
gptkbp:weight
|
149,000 Da
|
|
gptkbp:bfsParent
|
gptkb:certolizumab_pegol
|
|
gptkbp:bfsLayer
|
6
|